Severe trachomatous dry eye treatment

Article

Dr Mustafa Guzey and colleagues have found topical cyclosporine A to be effective in treating severe trachomatous dry eye in a recent study published in Clinical & Experimental Ophthalmology.

Dr Mustafa Guzey and colleagues have found topical cyclosporine A to be effective in treating severe trachomatous dry eye in a recent study published in Clinical & Experimental Ophthalmology.

In an author commentary published on MDLinx Dr Guzey confirmed that whilst there is no therapeutic treatment available at the moment for severe trachomatous dry eye: "In preliminary studies, treatment with topical CsA improved the signs and the symptoms of dry eye syndrome. An increase in goblet cell counts was reported in association with clinical improvement. Reduced numbers of activated T lymphocytes in conjunctiva and a decrease in IL's in conjunctival epithelium were also observed. CsA significantly improved corneal staining, Schirmer scores and significantly increased conjunctival goblet cell density."

Sixty four patients were included in the study and 32 were treated with CsA 0.05% ophthalmic emulsion twice daily and concomitant 5 times daily non-preserved artificial tear and the other 32 were designated as the control group receiving placebo emulsion twice daily and non-preserved artificial tear 5 times daily.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.